Caricamento quotazioni...
Previsioni
Il prezzo obiettivo medio degli analisti è 25,50 € (+14,35%). La mediana è 24,49 € (+9,82%).
| Acquista |
8 |
| Mantieni |
11 |
| Vendi |
1 |
Discussioni nella community
Non ci sono ancora discussioni su questo asset.
Avvia discussioneNotizie Vai al feed delle notizie
Envista rises premarket after JPMorgan upgrade and price-target increase
Envista shares rose about 2.3% premarket after JPMorgan upgraded the stock from “Neutral” to “Overweight” and raised the price target from $29 to $32. The bank cited improved operational execution and a valuation that lags recent fundamentals, and expects to set a mid‑term growth target slightly above the previous 2–4% range at the investor day on Sept. 17. Envista had already reported Q2 results that beat expectations on adjusted EPS and revenue and subsequently raised its full‑year forecast. » Altro su de.investing.com
Envista Holdings: CEO Paul Keel named chair of the board; executives receive special compensation
Envista Holdings named President and CEO Paul Keel effective immediately as chair of the board; Scott Huennekens remains lead independent director. The board approved a salary increase for Keel from $1.1 million to $1.3 million and a one-time equity award worth $10 million ($5 million RSUs, $5 million PSUs with a four-year vesting period). CFO Eric Hammes received PSUs worth $1.5 million with the same performance conditions. The actions are based on an SEC filing; Envista recently reported Q2 results and revenue above expectations and raised its full-year outlook. » Altro su de.investing.com
Envista raises 2026 outlook after Q2 sales, margin and EPS beat
Envista reported Q2 sales of $731 million, driven by 5% core revenue growth, with adjusted EBITDA up 28% and adjusted EPS of $0.41 (up 58%). Free cash flow was $105 million and the company repurchased about 2.4 million shares. Equipment and consumables led segment growth while Specialty Products saw strength from Spark clear aligners and implant investments. Management raised 2026 guidance to 3.5–4.5% core sales growth, 11–14% adjusted EBITDA growth and adjusted EPS of $1.50–$1.55, but warned China volume-based procurement could pressure pricing in H2. » Altro su finance.yahoo.com
Envista Holdings announces $300 million share buyback program and confirms outlook
Envista Holdings reports Q1 revenue growth (+14.4% nominal; organic +9.5% before special items), adjusted EBITDA of $98.9 million (+25%) and adjusted earnings per share of $0.36. Operating cash flow and free cash flow were negative, driven by higher investments in plants in China and Finland. Management confirms the full-year outlook (organic growth 2–4%, adjusted EBITDA +7–13%) and launches a new $300 million repurchase program through the end of 2029. The stock is likely to trade sideways in the short term; the next price catalysts are expected from the quarterly results on August 5. » Altro su finanzen.net
Envista Holdings named a top Ariel Investments pick after strong Q1 momentum
Ariel Investments lists Envista Holdings as a top stock to buy following a strong first quarter marked by 9.5% core revenue growth, 25% adjusted EBITDA growth and 50% EPS growth. Barclays reiterated an Overweight rating but trimmed its price target to $32 from $34. Envista reiterated full-year guidance with sales growth of 2–4%, adjusted EBITDA growth of 7–13% and adjusted diluted EPS guidance of $1.35–$1.45. » Altro su finance.yahoo.com
Dati finanziari dell'azienda
| (EUR) | ottobre 2026 | YoY |
|---|---|---|
| Ricavi | 614,16 Mln | 7,29% |
| Utile lordo | 355,79 Mln | 11,00% |
| Utile netto | 451,45 Mln | 1843,59% |
| EBITDA | 473,74 Mln | 529,28% |
Dati fondamentali
| Metrica | Valore |
|---|---|
Capitalizzazione di mercato | 3,58 Mld € |
Numero di azioni | 160,35 Mln |
Massimo/minimo a 52 settimane | 27,60 € - 17,03 € |
| Dividendi | No |
Beta | 0,94 |
Rapporto P/E | 6,26 |
Rapporto PEG | 0,00 |
Rapporto P/B | 1,28 |
Rapporto P/S | 1,37 |
Profilo aziendale
Envista Holdings Corporation, insieme alle sue controllate, si occupa dello sviluppo, della vendita e della commercializzazione di prodotti odontoiatrici negli Stati Uniti, in Cina e a livello internazionale. La società opera in due segmenti, Specialty Products & Technologies ed Equipment & Consumables. Il segmento Specialty Products & Technologies fornisce sistemi implantari dentali, sistemi di chirurgia guidata, biomateriali e protesi prefabbricate e su misura a chirurghi orali, protesisti e parodontologi con i marchi Nobel Biocare, Alpha-Bio Tec, Implant Direct, Nobel Procera e Orascoptic; e brackets e fili, tubi e bande, archi ortodontici, allineatori trasparenti, trattamenti ortodontici digitali, retainer e altri prodotti per laboratorio ortodontico con i marchi Damon, Insignia, AOA e Spark. Questo segmento offre inoltre pacchetti software, tra cui DTX Studio Implant per la pianificazione dei trattamenti di implantologia dentale; TX Studio Lab per la pianificazione dei trattamenti protesici; e DTX Studio Clinic per archiviare e consultare diverse immagini cliniche dei pazienti. Il segmento Equipment & Consumables fornisce attrezzature e forniture odontoiatriche, tra cui sistemi di imaging digitale, sensori, software e altri sistemi di visualizzazione/ingrandimento; sistemi endodontici e relativi materiali di consumo; materiali restaurativi, frese rotanti, materiali per impronte, agenti adesivi e cementi; e prodotti per la prevenzione delle infezioni. Questo segmento offre i propri prodotti con i marchi Dexis, Gendex, i-CAT, Kerr, Metrex, Total Care, Pentron, Optibond, Harmonize, Sonicfill, Sybron Endo e CaviWipes a studi dentistici, cliniche e ospedali. Envista Holdings Corporation è stata costituita nel 2018 e ha sede a Brea, in California.
| Nome | Envista Holdings |
| CEO | Paul A. Keel |
| Sede centrale | Brea,
ca Stati Uniti |
| Sito web | |
| Settore | Sanità |
| Industria | Attrezzature e forniture sanitarie |
| Quotazione in borsa | 18/09/2019 |
| Dipendenti | 12.000 |
Simboli di borsa
| Borsa | Simbolo |
|---|---|
XETRA | 0HV.DE |
NYSE | NVST |
Düsseldorf | 0HV.DU |
Frankfurt | 0HV.F |
München | 0HV.MU |
Toronto Stock Exchange | CLZ.V |
Pnk | ICRD |